Clinical trials: Recurrent Meningioma, open to volunteers
Grade 1 Meningioma, Grade 2 Meningioma
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Trial name
- NCT04082520
- Testing
- Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Intracranial Meningioma, Recurrent Meningioma
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive).
- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Trial name
- NCT02523014
- Testing
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib
- Where
- 791 sites in United States
- Volunteers
- 124 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Meningioma
Cabozantinib for Patients With Recurrent or Progressive Meningioma
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
- Trial name
- NCT05425004
- Testing
- Cabozantinib
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Baptist Health South Florida
Meningioma
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
- Trial name
- NCT07533942
- Testing
- JZP3507
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Jazz Pharmaceuticals
Recurrent Meningioma, Grade I and Grade II
Ceritinib Treatment for Recurrent Meningiomas
In this study, patients with recurrent grade I and grade II meningiomas will receive a daily dose of ceritinib for abour two years. Patients will visit the clinic on average about every 2 months for assessments.
- Trial name
- CURE-M (NCT07893197)
- Testing
- Ceritinib
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Kevin Petrecca
Meningioma, Meningioma, Malignant
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back…
- Conditions
- Meningioma, Meningioma, Malignant, Recurrent Meningioma
- Trial name
- SRS-AIM (NCT06557512)
- Testing
- Hypofractionated Stereotactic Radiosurgery (SRS), Magnetic Resonance Imaging (MRI), Computed Tomography (CT)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Recurrent Meningioma
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come…
- Trial name
- NCT07150806
- Testing
- Actinium Ac 225 DOTATATE RYZ101, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua Palmer
Meningioma
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Meningiomas are known to be the most frequent intracranial neoplasms and account for approx. 25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled somatostatin analogues, also called Peptide Receptor…
- Trial name
- PROMENADE (NCT04997317)
- Testing
- 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4, 177Lu-DOTA-JR11 (Phase I/II)
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Basel, Switzerland
Meningioma
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
- Trial name
- STELLAR-201 (NCT07428616)
- Testing
- Zanzalintinib
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Exelixis
Meningioma
Measurement of PSMA Expression in Vivo in Recurrent Meningiomas by PET Imaging: a Preliminary Study to a Therapeutic Trial Using Radioligand Therapy (RLT)
Meningioma is the most common intracerebral tumor in adults. Conventional treatment includes surgery and external beam radiation therapy.
- Trial name
- PIVIM (NCT07428213)
- Testing
- PET PSMA
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Residual, Progressive or Recurrent Grade II or III Meningioma
NEO100 and High-Grade Meningioma
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade…
- Trial name
- NCT05023018
- Testing
- NEO100
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neonc Technologies, Inc.
Grade 1 Meningioma, Grade 2 Meningioma
Comparing Radiation After Surgery to Observation After Surgery in Patients With Clinical Low-Risk, Molecular High-Risk Meningioma, and Evaluating Observation After Surgery in Patients With Clinical and Molecular Low-Risk Meningioma
This phase III trial compares post-surgical surveillance to post-surgical radiation therapy for improving survival without disease progression in clinically low-risk patients with a grade 1 meningioma that is new or that has come…
- Conditions
- Grade 1 Meningioma, Grade 2 Meningioma, Recurrent Grade 1 Meningioma
- Trial name
- NCT07785687
- Testing
- Patient Observation, Magnetic Resonance Imaging, Biospecimen Collection
- Volunteers
- 464 people
- Sponsor
- NRG Oncology
High Grade Meningioma
A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas
This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and safety of SYHA1813 versus treatment of investigators' choice in patients with recurrent or progressive…
- Trial name
- NCT07613450
- Testing
- SYHA1813, Investigator's Choice Treatment
- Volunteers
- 136 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Recurrent or Progressive High Grade Meningioma
A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma
This is a randomized, controlled, open-label, multicenter, Phase II clinical study designed to evaluate the efficacy and safety of SYHA1813 compared to investigators' choice in participants with recurrent or progressive…
- Trial name
- NCT06739213
- Testing
- SYHA1813, Investigator's Choice Treatment
- Volunteers
- 56 people
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Central Nervous System Neoplasms, Glioblastoma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting…
- Conditions
- Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma
- Trial name
- NCT04541082
- Testing
- ONC206
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jazz Pharmaceuticals
Recurrent Meningioma
177Lu-DOTATATE for Recurrent Meningioma
Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation.
- Trial name
- LUMEN-1 (NCT06326190)
- Testing
- Local standard of Care, 177Lu-DOTATATE
- Where
- 19 sites in Austria, France and 4 more
- Volunteers
- 136 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Meningioma
Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study
The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and/or cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.
- Trial name
- BIOLIMEN-1 (NCT07398170)
- Testing
- Blood sampling, Lumbar puncture
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Montpellier
Meningioma, Malignant
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent meningiomas.
- Trial name
- MIRAGE (NCT06275919)
- Testing
- Regorafenib 40 MG Oral Tablet, Local Standard of Care
- Where
- 20 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Istituto Oncologico Veneto IRCCS